1-4 of 4
Yury L. Shevchenko
Close
Sort by
Journal Articles

Which Strategy of Immunoablative Therapy with Autologous Stem Cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.

Yury L. Shevchenko, Andrei A. Novik, Alexey N. Kuznetcov, Boris A. Afanasiev, Igor A. Lisukov, Oleg A. Rykavicin, Alexandr A. Myasnikov, Tatyana I. Ionova, PhD, Vladimir J. Melnichenko, MD, PhD, Denis A. Fedorenko, MD, PhD, Anton V. Kishtovich, PhD, Roman A. Ivanov, PhD, Gary J. Gorodokin, MD
Journal: Blood
Blood (2007) 110 (11): 5093.
https://doi.org/10.1182/blood.V110.11.5093.5093
Published: 2007
Journal Articles

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Yury L. Shevchenko, Andrei A. Novik, Alexey N. Kuznetcov, Boris V. Afanasiev, Igor A. Lisukov, Oleg A. Rykavicin, Alexandr A. Myasnikov, Tatiana I. Ionova, PhD, Sergey V. Shamanski, MD,PhD, Andrey D. Kulagin, MD,PhD, Olga A. Malysheva, MD, Nikolay I. Baziy, MD,PhD, Vladimir Y. Melnichenko, MD,PhD, Denis A. Fedorenko, MD,PhD, Inna V. Vereschagina, MD, Andrey E. Zdorov, MD, Anton V. Kishtovich, PhD, Roman A. Ivanov, PhD, Yury N. Fedotov, MD,PhD, Gary I. Gorodokin, MD
Journal: Blood
Blood (2006) 108 (11): 3072.
https://doi.org/10.1182/blood.V108.11.3072.3072
Published: 2006
Journal Articles

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andrei A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Tatiana I. Ionova, PhD, Andrei D. Kulagin, MD, Olga A. Malysheva, MD, Gennady N. Bisaga, MD, PhD, Vladimir J. Melnichenko, MD, PhD, Sergei V. Voloshin, MD, PhD, Denis A. Fedorenko, MD, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD, Yury N. Fedotov, MD, PhD, Gary I. Gorodokin, MD
Journal: Blood
Blood (2005) 106 (11): 5467.
https://doi.org/10.1182/blood.V106.11.5467.5467
Published: 2005
Journal Articles

Clinical and Quality of Life Outcomes in Patients with Multiple Sclerosis (MS) after High Dose Chemotherapy(HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andri A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Yury N. Fedotov, MD, Tatiana I. Ionova, PhD, Alexandr D. Kulagin, PhD, Olga A. Malysheva, MD, Gennadi N. Bisaga, PhD, Vladimir Y. Melnichenko, PhD, Lubov V. Chelombit, MD, Sergei V. Voloshin, PhD, Denis A. Fedorenko, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD
Journal: Blood
Blood (2004) 104 (11): 1875.
https://doi.org/10.1182/blood.V104.11.1875.1875
Published: 2004